The aim of the UCB Investigator-Initiated Studies (IIS) program is to support unsolicited, and independently initiated and conducted, studies that have the potential to enhance medical and scientific knowledge.
UCB is primarily focused on the following areas of therapeutic expertise (alphabetically listed):
|Ankylosing Spondylitis||Parkinson's Disease|
|Axial Spondyloarthritis||Psoriatic Arthritis|
|Crohn's Disease||Restless Legs Syndrome|
|Low Bone Mass Disorder||Systemic Lupus Erythematosus|
UCB will also consider innovative ideas that enhance patient care and advance scientific knowledge.
UCB support may be provided in the form of funding and/or investigational drugs (product or compound manufactured/owned by UCB).
|Month in Review||Review Type||Submission Due Date|
|January||Concept||27 December 2016|
|February||Concept||30 January 2017|
|March||Concept||15 February 2017|
|April||Concept||20 March 2017|
|May||Concept||20 April 2017 (Immunology Only)|
|June||Concept||29 May 2017 (Immunology Only)|
|July||Concept||21 June 2017|
|August||Concept||24 July 2017|
|September||Concept||21 August 2017 (Immunology Only)|
|October||Concept||20 September 2017|
|November||Concept||25 October 2017|
|December||Concept||20 November 2017 (Immunology Only)|
UCB is using the eRequest on-line submission portal to manage all Investigator-Initiated Study requests worldwide. To submit a concept, please click here: erequest.ucb.com
If a concept is recommended for a full proposal submission, an IIS Team member will contact the applicant with instructions.
eRequest is available for IIS submissions worldwide.
You can contact your local UCB Medical Science Liaison or UCB Medical Affairs office in your country.
All IIS process queries should be sent to IISmailbox@ucb.com.